Both in Biotechnology
Beam Therapeutics vs BioCryst Pharmaceuticals
Over the past year BEAM returned +12.3% and BCRX returned +23.5%; their daily moves had a correlation of 0.27.
BEAM +12.3% BCRX +23.5%Growth of $1, one year, split-adjusted
| Metric | BEAM | BCRX |
|---|---|---|
| Price | $27.23 | $8.47 |
| Market cap | $2.81B | $2.16B |
| Today | −5.58% | −0.59% |
| 1 month | +11.6% | +4.3% |
| 6 months | −11.3% | −7.8% |
| Year to date | −1.8% | +8.6% |
| 1 year | +9.9% | +15.9% |
| Revenue growth (YoY) | −94.2% | +33.6% |
| Gross margin | 100.0% | 98.2% |
| Net margin | −25036.3% | 35.9% |
| P/E (TTM) | — | — |
| Price / sales | 18.0× | 2.3× |
| Net cash | $1.05B | -$471.6M |
| Dividend yield | — | — |
| Volatility (60d) | 62.4% | 45.1% |
| Short % of float | 32.0% | 10.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).